Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Nuvalent’s First-of-Its-Kind NVL-520 Receives Breakthrough Therapy Designation from U.S. FDA
Nuvalent, a biopharmaceutical company in the clinical stage, has declared that the U.S. Food and Drug Administration has accorded breakthrough therapy designation to NVL-520 for treating individuals...
Iovance Biotherapeutic’s Novel Lifileucel (AMTAGVI™) Receives FDA Approval for Advanced Melanoma Treatment
Iovance Biotherapeutics, a leading biotechnology company committed to pioneering, developing, and delivering innovative polyclonal tumor infiltrating lymphocyte cell therapies for cancer patients...
Latozinemab Secures FDA Breakthrough for FTD-GRN in Progranulin Gene Mutation
Alector recently announced a significant milestone in the potential treatment of Frontotemporal Dementia with a progranulin gene mutation. The U.S. Food and Drug Administration...
Ensysce Biosciences Secures FDA Breakthrough for PF614-MPAR in a Novel Advancement
Ensysce Biosciences, a clinical-stage company dedicated to enhancing prescription drug safety through innovative chemistry, has received notification from the U.S. Food and Drug Administration...
Santhera's AGAMREE® (Vamorolone) Granted First-of-Its-Kind Approval for Duchenne Muscular Dystrophy in the UK
Santhera Pharmaceuticals has recently announced the approval of AGAMREE® in the United Kingdom for the treatment of Duchenne muscular dystrophy in patients aged 4 and above, irrespective of their underlying mutation...
Coherus Novel UDENYCA ONBODY™ System Approved by FDA for pegfilgrastim-cbqv
Coherus BioSciences, a biopharmaceutical company in the commercial stage, has received approval from the U.S. Food and Drug Administration for its UDENYCA ONBODY. This is an on-body injector presentation of UDENYCA...
Evaxion to Develop Novel Personalized Cancer Vaccines Using AI-Unearthed Targets
Evaxion Biotech, a pioneering clinical-stage TechBio company, specializes in developing AI-Immunology™ powered vaccines. Recently, the company announced an enhanced dedication to crafting tailored cancer vaccines...
Geneseeq receives FDA Breakthrough Designation for Novel CanScan™ Multi-cancer Detection Solution
Geneseeq recently announced that its multi-cancer early detection solution, CanScan™, has received Breakthrough Device Designation from the US Food and Drug Administration...
Bristol Myers Squibb's Abecma® Approved as First CAR T Therapy for Earlier Treatment in Japan for Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb has recently obtained regulatory approval for an expanded indication of Abecma® , a chimeric antigen receptor T cell therapy targeting B-cell maturation antigen...
UK MHRA Approves Novel CASGEVY™, the First CRISPR/Cas9 Gene-Editing Therapy
The UK Medicines and Healthcare products Regulatory Agency (MHRA) recently granted approval for CASGEVY™, marking a groundbreaking development as the first-ever therapy utilizing CRISPR/Cas9 gene-editing technology to treat sickle cell disease...
